Muzaffar H Qazilbash
Overview
Explore the profile of Muzaffar H Qazilbash including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
171
Citations
2550
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akhtar O, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, et al.
Blood Adv
. 2025 Jan;
PMID: 39786391
Idecabtagene vicleucel (ide-cel) is an anti-BCMA CAR-T cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM) after 2 prior lines of therapy. There is limited data on outcomes of...
2.
Pasvolsky O, Marcoux C, Wang Z, Milton D, Pal B, Tanner M, et al.
Transplant Cell Ther
. 2025 Jan;
31(3):166.e1-166.e9.
PMID: 39746546
Patients with multiple myeloma (MM) without high-risk cytogenetic abnormalities are classified as having standard-risk MM (SRMM), and data focusing on their outcomes after autologous hematopoietic stem cell transplantation (autoHCT) are...
3.
Pattali S, Hu S, Bashir Q, Champlin R, Qazilbash M
Cureus
. 2024 Dec;
16(11):e73583.
PMID: 39677110
The synchronous presentation of chronic myeloid leukemia (CML) and multiple myeloma (MM) is extremely rare. CML is a myeloproliferative neoplasm originating from an abnormal pluripotent hematopoietic stem cell. It is...
4.
Marcoux C, Pasyar S, Milton D, Khan H, Tanner M, Bashir Q, et al.
Br J Haematol
. 2024 Nov;
206(2):763-765.
PMID: 39610225
No abstract available.
5.
Pasvolsky O, Marcoux C, Milton D, Pal B, Tanner M, Bashir Q, et al.
Blood Cancer J
. 2024 Nov;
14(1):189.
PMID: 39482325
Autologous transplantation remains the standard of care for eligible multiple myeloma (MM) patients, yet optimal CD34 cell dose remains unclear. We conducted a retrospective study on MM patients undergoing upfront...
6.
Marcoux C, Pasvolsky O, Milton D, Tanner M, Bashir Q, Srour S, et al.
Transplant Cell Ther
. 2024 Oct;
31(1):12.e1-12.e10.
PMID: 39448031
Despite tremendous advancements in multiple myeloma (MM) therapeutics, outcomes remain heterogeneous, heavily influenced by clinical and cytogenetic factors. Among these, deletion of the short arm of chromosome 17 (del(17p)) is...
7.
Pasvolsky O, Marcoux C, Dai J, Milton D, Tanner M, Syed N, et al.
Transplant Cell Ther
. 2024 Jun;
30(8):772.e1-772.e11.
PMID: 38852784
Upfront autologous stem cell transplantation (auto-SCT) remains standard of care for eligible patients with newly diagnosed multiple myeloma (NDMM), although recently its role has been questioned. The aim of the...
8.
Pasvolsky O, Wang Z, Milton D, Tanner M, Bashir Q, Srour S, et al.
Blood Cancer J
. 2024 May;
14(1):82.
PMID: 38760362
Autologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). Although most patients eventually progress after autoHCT, a small proportion achieve a durable response....
9.
Alzahrani K, Pasvolsky O, Wang Z, Milton D, Tanner M, Bashir Q, et al.
Br J Haematol
. 2024 Mar;
204(5):1944-1952.
PMID: 38448009
The second revision of the International Staging System (R2-ISS) is a simple tool to risk-stratify newly diagnosed multiple myeloma (NDMM) patients. Here, we completed a retrospective analysis to evaluate the...
10.
Malek A, Al-Juhaishi T, Milton D, Ramdial J, Daher M, Olson A, et al.
Bone Marrow Transplant
. 2024 Feb;
59(5):699-704.
PMID: 38355908
No abstract available.